Robert F. Kennedy Jr.

With the gray market, you have no idea.

And a lot of this stuff that we've looked at is just, you know, is very, very substandard.

I'm very anxious to move, probably not all of those peptides, some of them are in litigation, but about 14 of them back to making them more accessible.

And FDA is in the middle of, I think, within a couple of weeks, we will have announced some kind of new action.

And my hope is that

They're going to end up with – they're still looking at the science.

My hope is that they're going to get moved to a place where people have access from ethical suppliers.

And it's a very dangerous black market.

How many people are alcoholics?

I don't know enough, and I don't think it's well-documented enough about whether it's a long-term impact on addiction.

But—

In terms of just sort of the field of psilocybin and MDMA

There are lots and lots of good studies now that clearly demonstrate that or strongly suggest that it is effective against PTSD and also some forms of depression, etc.,

And so I would say everybody in my agency and over at VA, at Doug Collins' agency, is very anxious to get a rule out there that will allow these kind of studies, will allow access under therapeutic settings, particularly to the military.

soldiers who have suffered these injuries to get access to these products.

We're working through that process now.

You know, you have Marty McCary.

I mean, we're all working on it and trying to make it happen.

If you can treat depression without using SSRIs, putting somebody a lifetime sentence to SSRIs, you can treat them.

There's a number of things, not just psychedelics, but a number of interventions that we're looking at that are rapid interventions.